1	N-Palmitoyl glycine activates transient receptor potential
2	channel 5 and increases the risk of Brugada syndrome
3	
4	Running title: N-Palmitoylglycine and TRPC5 in Brugada syndrome
5	
6	Hongxuan Xu, PhD <sup>1,2*</sup> , Bingxun Li, PhD <sup>1,2*</sup> , Ying Chen, PhD <sup>1,2</sup> , Yanyun Lin, PhD <sup>1,2</sup> ,
7	An Zhang, PhD <sup>1,2</sup> , and Lin Wu, MD <sup>1,2,3#</sup>
8	
9	<sup>1</sup> Department of Cardiology, Peking University First Hospital, Beijing, China.
10	<sup>2</sup> State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University
11	<sup>3</sup> Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute of
12	Cardiovascular Research, Southwest Medical University, Luzhou, China.
13	
14	#Corresponding author: Lin Wu; E-mail: <u>wuepgroup@126.com</u> ; address: NO.8
15	Xishiku Street, Department of Cardiology, Peking University First Hospital, Beijing,
16	China.
17	
18	*These authors contributed equally to this study.
19	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 20 Abstract

### 21 Background

22 Brugada syndrome (BrS) is an arrhythmic disorder associated with an increased risk of sudden 23 cardiac death; however, current treatment options are limited due to their side effects and variable 24 efficacy. 25 Methods 26 In this study, we first employed Mendelian randomization analysis utilizing proteomic, 27 transcriptomic, and metabolomic data to identify potential therapeutic targets for BrS. Ex vivo 28 perfused heart models were used to assess the effects of the potential targets on action potentials 29 and QT intervals. Calcium indicators were employed to evaluate calcium homeostasis in primary 30 cardiomyocytes, and patch-clamp techniques were used to investigate the impact on Nav1.5 and 31 TRPC5 channels.

32 Results

33 Our findings indicate that N-palmitoyl glycine (PalGly) is linked to an increased risk of BrS and 34 interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, 35 CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA. Electrophysiological experiments 36 showed that although PalGly does not interact with Nav1.5, it enhances calcium sparks in 37 ventricular cardiomyocytes. We determined that the calcium-modulating effect of PalGly is 38 mediated by its binding to and activation of the transient receptor potential channel 5 (TRPC5) 39 channel. Furthermore, PalGly was found to shorten the QT interval and action potential duration 40 in Langendorff-perfused rabbit hearts and isolated rabbit cardiomyocytes. Transcriptomic and 41 lipidomic analyses of PalGly-treated neonatal rat cardiomyocytes revealed significant negative

42 modulation of immune pathways, akin to the effects observed with agonizing TRPC5.

### 43 Conclusion

- 44 Our study underscores the involvement of PalGly, TRPC5, and inflammation-related proteins in
- 45 the pathophysiology of BrS.

46

## 48 Introduction

49	Brugada syndrome (BrS) is a rare arrhythmic disorder with an increased risk of sudden death,
50	characterized by hallmark ST-segment elevation in the right precordial leads of the
51	electrocardiogram (ECG) <sup>1</sup> . BrS is traditionally considered an inherited channelopathy with a
52	Mendelian autosomal dominant pattern. However, the penetrance and causative effect of reported
53	BrS-related genetic variants is often uncertain. The phenotypes of one variant can be discordance
54	between probands and their family members <sup>2</sup> . Current treatments for BrS including antiarrhythmic
55	medication, implantable cardioverter-defibrillator (ICD), and catheter ablation are limited by their
56	side effects and effectiveness <sup>3</sup> . Especially for asymptomatic patients who present typical BrS
57	pattern ECG, these strategies are far from optimal to prevent a likely fatal incidence. In this study,
58	we first use Mendelian randomization (MR) analysis based on proteomics, transcriptomics, and
59	metabolomics to explore potential causal targets for BrS, and then we test our findings with in
60	vitro and ex vivo electrophysiological experiments.

## 61 Methods

## 62 BrS cohort and ECG-wide association study

Summary-level statistics for BrS were obtained from a meta-analysis study comprising 2,820
unrelated cases and 10,001 controls of European ancestry<sup>4</sup>. The diagnosis followed the guidelines
from the 2013 Heart Rhythm Society, European Heart Rhythm Association and Asia Pacific Heart
Rhythm Society expert consensus statement<sup>5</sup>, the 2015 European Society of Cardiology
guidelines<sup>6</sup> and the 2017 American Heart Association guidelines<sup>7</sup>. Inclusion criteria required a type

68 1 BrS ECG, characterized by coved-type ST elevation at baseline (spontaneous) or after a drug 69 challenge test, in one or more leads of the right precordial leads (V1 and/or V2), either in the 70 standard (fourth intercostal space) or higher positions (second or third intercostal spaces). 71 Diagnostic ECGs were centrally reviewed by a cardiac electrophysiologist experienced in BrS to 72 confirm that the diagnostic criteria were met. The genetic associations were adjusted for the first 73 six genetic principal components, SNPs that were missing in four or more of the ten strata, as well 74 as those with a heterogeneity test P < 1e-6 were excluded. Top variants of significant exposures were looked up in ECGenetics (http://www.ecgenetics.org)<sup>8</sup> to explore their effect on R-R 75 76 adjusted three-lead exercise electrocardiogram (ECG) morphology. The GWAS for ECG 77 morphology consists of comprehensive deep phenotyping of 77,190 ECGs in the UK Biobank 78 across the complete cycle of cardiac conduction, resulting in 500 spatial-temporal data points. 79 Summary-level statistics for QTc consists of 84 630 UK Biobank pariticipants<sup>9</sup>.

### 80 Multi-omics GWAS data source

81 Summary-level statistics of genome-wide association studies (GWAS) for two protein quantitative trait loci (pQTL) studies were obtained from deCode genetics<sup>10</sup> and UKB-PPP<sup>11</sup>. Proteomics from 82 83 deCode genetics consists of 4,907 circulating proteins in 35,559 Icelanders measured by 84 SOMAscan version 4. Proteomics from UKB-PPP consists of 2,923 circulating proteins measured 85 by Olink technology in 54,219 UK Biobank participants with the most European ancestry (around 86 95%). The protein level of these two studies was inverse rank normalized to perform 87 covariates-adjusted genetic association. In addition, eOTL data was obtained from the eOTLgen 88 Consortium which measured transcriptomics by arrays and RNA-seq from 311,684 blood and

PBMC (peripheral blood mononuclear cell) samples (Predominantly European ancestry)<sup>12</sup>.
Summary-level statistics of genetic associations with inverse rank normalized levels of 1,091
blood metabolites and 309 metabolite ratios quantified by the Metabolon HD4 platform in 8,299
unrelated European ancestry individuals from the Canadian Longitudinal Study on Aging (CLSA)
cohort<sup>13</sup> were obtained.

## 94 Cardiometabolic traits

95 A total of 28 cardiometabolic traits were included, including lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), 96 apolipoprotein A1 and B (ApoA1, ApoB), and lipoprotein A Lp(a))<sup>14,15</sup>, blood pressure (systolic 97 98 blood pressure (SBP), and diastolic blood pressure (DBP))<sup>16</sup>, glycemic traits (fasting glucose, fasting insulin, 2-hour post-challenge glucose, and HbA1c)<sup>17,18</sup>, and anthropometric traits (body 99 mass index (BMI), waist circumference, hip circumference, and waist-to-hip ratio)<sup>19</sup>. With 11 100 101 cardiometabolic diseases, including atrial fibrillation (AF), stroke and stroke subtypes (large artery atherosclerosis, small-vessel, and cardioembolic)<sup>20</sup>, coronary heart disease (CHD)<sup>21</sup>, heart failure 102 (HF)<sup>22</sup>, aortic aneurysms<sup>23</sup>, chronic kidney disease<sup>24</sup>, type 1 diabetes<sup>25</sup> and type 2 diabetes<sup>26</sup>. Most 103 participants in these cohorts were of European ancestry (Table S1). 104

## 105 Exposure instrument variables selection

106 Genome-wide suggestive SNPs (p < 1e-6) in weak linkage disequilibrium ( $r^2 < 0.1$ , based on the 107 1000 Genomes Phase 3 European reference panel) within  $\pm 1$  Mb from target gene loci associated 108 with the proteins were obtained. Independent effect SNPs for metabolites QTL were identified by 109 genome-wide suggestive threshold (p < 1e-6) and were clumped by a 1Mb distance with a linkage

110 disequilibrium threshold  $r^2 = 0.1$ . Clumping was performed by Plink version  $1.9^{27}$ . F-statistics of 111 less than ten were used to exclude SNPs that were weak instruments for a limited proportion of the 112 variance explained.

## 113 MR analysis

114 The included cohorts consist of almost European ancestry, no individuals likely to overlap. 115 Two-sample MR analysis based on indexed SNPs for circulating proteins, RNAs, and metabolites 116 was used to capture the associations with the risk of BrS. An inverse variance weighted (IVW) 117 random-effects model was employed to estimate the causal effects of genetically proxied targets 118 on BrS. Bonferroni correction was used to account for multiple tests. Weighted median, MR Egger 119 and Steiger test were used to employ sensitivity analysis, heterogeneity test, and causal direction 120 test. All MR analyses were performed in R version 4.3.2 by TwoSampleMR package<sup>28</sup>. Findings 121 were reported according to the STROBE-MR (Strengthening the Reporting of Mendelian 122 Randomization Studies) guidelines<sup>29</sup>.

## 123 Colocalization analysis

Colocalization analysis was employed by the coloc R package<sup>30</sup> to test whether identified exposures and BrS were associated and shared the same causal variant within  $\pm 1$  Mb from target gene loci associated with the proteins. We set prior probabilities of the SNP being only associated with exposure (p1) or outcome (p2) at 1e-4; and the probability of the SNP being associated with both traits (p12) at 1e-5, posterior probability for shared causal variants (PPH4)  $\ge 0.8$  were considered to have strong evidence of colocalization. The set of significant genes and proteins with high colocalization support was set forth to an overrepresentation analysis using the

- pathways described in the Gene Ontology and the KEGG database. Selected pathways were those
- 132 significantly enriched at an FDR <0.05.

## 133 Mediation analysis

We explored the mediation effect of circulating proteins on BrS via metabolites using the delta method to approximate confidence intervals by the RMediation package<sup>31</sup>. The MR estimate for the mediated effect of genetically predicted levels of circulating metabolites on BrS was divided by the total effect of genetically predicted levels of circulating proteins on BrS risk estimated in the IVW univariable MR, with standard errors estimated using the propagation of error method to calculate mediation proportion.

## 140 Molecular Docking

- 141 The 3D structures of DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA
- 142 were obtained from RCSB Protein Data Bank (PDB ID: 2ED7, 2ED8, 2ED9, 2EDB, 2EDD,
- 143 2EDE, 2MCY, 2MCZ, 3AI8, 1HUC, 6DXW, 6DXX, 1IJV, 2K1K, 2K1L, 7WRQ, 4MXV, 4MXW)
- 144 and was subjected to processing through the pdb2pqr before initiating the docking analysis. The
- 145 entire docking process was conducted using Autodock vina 1.2.0 by Dockey graphical interface<sup>32</sup>
- 146 with default parameters. The visualization was performed by PyMOL 3.0.3.

## 147 Isolation of rabbit cardiomyocytes

Rabbit ventricular cardiomyocytes were isolated enzymatically, as previously described<sup>33</sup>. The
animal used in this study conformed to the "Guide for the Care and Use of Laboratory Animals"
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 2011). The

151 ethical clearance was granted by the Institutional Animal Care and Use Committee of Peking 152 University First Hospital (approved number: J2024090), affirming the conscientiousness of their 153 treatment and welfare. Male New Zealand rabbits weighing 2.5 to 3.0 kg (approximately 154 3-month-old, Fangyuanyuan, China) were anaesthetized with xylazine (16 mg/kg, Huamu; China) 155 and ketamine (40 mg/kg CAHG; China) (IV) and injected with 5,000 units/kg of heparin. The 156 absence of pain response and corneal reflex served as the indicators to ascertain the appropriate 157 level of anaesthesia depth. Rabbit hearts were rapidly excised and retrogradely perfused through 158 the aorta on a standard Langendorff apparatus for 10 min at a flow rate of 10 mL/min with a 159 calcium-free Tyrode solution continuously gassed with 100% O2 at 37 °C. The hearts were 160 perfused in a recirculating manner for 40-60 min (ventricular cardiomyocytes) with 100 mL of 161 calcium-free Tyrode solution containing 60 mg of collagenase (type II, Sigma) and 100 mg of 162 bovine serum albumin (BSA, Sigma). The enzymes were washed out for 5 min via perfusion with 163 a calcium-free Tyrode solution. The ventricles were cut into small chunks, and the tissue was 164 manually pipetted with a disposable plastic transfer pipette for 1-2 min to mechanically separate 165 the cells. The cell and enzyme mixture were filtered through a 200-micron nylon mesh into 166 centrifuge tubes and the cells were stored in KB solution. Cells of approximately the same length 167 and with clear stripes, a rod shape, a clean and smooth surface, and no spontaneous contractions 168 over 1 minute of observation were selected for use in the experiments. The animal use was 169 approved by the Institutional Animal Care and Use Committee of Peking University First Hospital. 170 The isolated cardiomyocytes were then incubated with N-palmitoyl glycine (MedChemExpress) 171 for at least 15 min to study its effect on action potential and calcium spark.

## 172 Isolated Rabbit Heart Assay

173	Following the excision, the heart was carefully removed and perfused with a specially modified
174	Krebs-Heinsleit (K-H) perfusate (pH 7.4, gassed with 95% O <sub>2</sub> and 5% CO <sub>2</sub> ) that was prewarmed
175	to 37 °C at a controlled speed of 20 mL/min after the aorta was cannulated. The K-H solution
176	contained (in mM) 118 NaCl, 2.8 KCl, 1.2 KH <sub>2</sub> PO <sub>4</sub> , 2.5 CaCl <sub>2</sub> , 0.5 MgSO <sub>4</sub> , 2.0 sodium pyruvate,
177	5.5 glucose, 0.57 Na2EDTA, and 25 NaHCO <sub>3</sub> . To ensure successful electrical pacing, the right
178	atrium was partially removed and the whole atrioventricular block was induced by
179	thermo-ablating the atrioventricular nodal area. A custom-made bipolar Teflon-coated electrode
180	was placed on the right ventricular septum to pace the heart. Electrical stimuli, 3 ms in width and
181	3-fold threshold amplitude were delivered to the pacing electrode at a frequency of 1 Hz using an
182	EP-4 stimulator (EP MedSystems, ST. JUDE MEDICAL). After ventricular pacing was initiated, a
183	30-minute period was allowed for the equilibration of heart rhythm to achieve a stable and
184	consistent rhythm before the subsequent measurements or interventions. Pressure-contact Ag-
185	AgCl MAP electrodes were placed on the epicardial and endocardial ventricular walls,
186	respectively. The ventricular MAP and pseudo-ECG were continuously monitored, amplified,
187	filtered, and digitized in real-time using a BIOPAC Systems MP 150 signal processor and
188	displayed on a computer screen using the AcqKnowledge 4.2 for MP150 software (BIOPAC
189	Systems, Inc.). The duration of the monophasic action potential at 30, 50, and 90% repolarization
190	(MAPD30/50/90) was used to monitor left ventricular repolarization. The MAPD30/50/90 was
191	measured at the steady state following the PalGly perfusion.

### Whole-Cell Voltage-Clamp Recordings of Na<sub>v</sub>1.5 Channels 192 in HEK293T Cells 193

194 The HEK293T cells were grown in culture dishes for 24 h, and plasmids expressing  $Na_{\rm V}1.5$ 195 (NM 198056) were transfected into HEK293T (National Collection of Authenticated Cell 196 Cultures, China) cells using lipofectamine 3000 (Thermo Fisher Scientific). The extracellular 197 Solution (mM) contained: 137 NaCl, 1 MgCl<sub>2</sub>·6H<sub>2</sub>O, 4 KCl, 1.8 CaCl<sub>2</sub>·2H<sub>2</sub>O, 10 D-Glucose, 10 198 mM HEPES, adjusted to pH 7.4 with NaOH. The intracellular Solution (mM) contained: 50 CsCl, 199 60 CsF, 10 HEPES, 20 EGTA, and 10 NaCl, adjusted to pH 7.2 with CsOH. Patchmaster software, 200 coupled with an EPC-10 amplifier (EPC-10, Heka Electronic, Germany), was used to collect and 201 store electrophysiological data. Electrodes (1-3 M $\Omega$ ) were pulled from 1.5-mm borosilicate glass 202 filaments using a P1000 micropipette puller. The holding potential was set at -120 mV, with a 203 series of square-wave pulses from -120 to -10 mV in 10 mV increments for 8000 ms, followed by 204 a step to -10 mV for 30 ms, and then returning to -120 mV. The data were fitted to the Boltzmann 205 equation to derive the steady-state inactivation curve. The holding potential was set at -120 mV, 206 followed by depolarization to 0 mV for 20 ms to stimulate the resting-state sodium channel 207 current. The voltage was then stepped to the condition pulse voltage corresponding to the 208 half-inactivation voltage  $(V_{1/2})$  for 8000 ms, followed by repolarization to -120 mV for 30 ms. 209 Subsequently, depolarization to 0 mV for 20 ms stimulated the half-inactivated state sodium 210 channel current. Finally, the potential was returned to -120 mV, with current recordings taken 211 every 20 seconds. Once steady-state current values were achieved, cumulative drug application 212 was performed, starting with negative control (0.1% DMSO) followed by 1 µM PalGly.

### Whole-Cell Voltage-Clamp Recordings of TRPC5 Channels 213 in HEK293 Cells 214

215 The HEK293T cells (China Infrastructure of Cell Line Resource) were grown in culture dishes for 216 24 h, and plasmids expressing hTRPC5 (NM 012471) were transfected into HEK293T cells using 217 lipofectamine 3000. The extracellular Solution (mM) contained: 145 NaCl, 4 KCl, 1 MgCl<sub>2</sub>·6H<sub>2</sub>O, 218 2 CaCl2·2H2O, 10 D-Glucose, 10 HEPES, adjusted to pH 7.4 with NaOH. The intracellular 219 Solution (mM) contained: 120 Cs-aspartic acid, 20 CsCl, 2 MgCl<sub>2</sub>·6H<sub>2</sub>O, 8.8 CaCl<sub>2</sub>·2H<sub>2</sub>O, 10 220 EGTA, 10 HEPES, 2 Na<sub>2</sub>-ATP, adjusted to pH 7.2 with CsOH. Once a whole-cell seal is 221 established, the cell membrane potential is clamped at -80 mV. The voltage is stepped from 0 mV 222 to -100 mV and maintained for 1 ms, followed by a ramp to 100 mV for 300 ms, and then 223 repolarized to 0 mV for 50 ms. Data collection is repeated every 10 seconds to observe the effects 224 of the PalGly on the TRPC5 current.

### Whole-cell current recording for ventricular cardiomyocytes 225

226 The extracellular Solution (mM) contained: 137 NaCl, 4 KCl, 10 HEPES, 10 D-Glucose, 1 227 MgCl<sub>2</sub>·6H<sub>2</sub>O, 2 CaCl<sub>2</sub>·2H<sub>2</sub>O, adjusted to pH 7.4 with NaOH. The intracellular Solution (mM) 228 contained: 135 KCl, 2 MgCl<sub>2</sub>·6H<sub>2</sub>O, 10 HEPES, 1 EGTA, 4 Mg-ATP, 0.3 NaGTP, adjusted to pH 229 7.2 with KOH. All the experiments were performed at a temperature of  $23 \pm 1$  °C. For ventricular 230 cardiomyocytes, the cells are clamped at -80 mV, and the recording is switched to the current 231 clamp mode with I = 0. Ventricular myocytes require stimulation to generate action potentials. The 232 parameters for the inward current pulse stimulation are as follows: duration of 10 ms and 233 stimulation amplitude ranging from 0.1 to 1 nA.

## 234 Measurements of Ca<sup>2+</sup> sparks

235 Isolated cardiomyocytes were subjected to a fluorescent calcium indicator, Fluo-4-AM 236 (Invitrogen), for 15 minutes at room temperature. Following this incubation period, the cells 237 underwent centrifugation, after which the supernatant was carefully removed. The cells were then 238 resuspended in fresh Tyrode solution containing 250 µmol/L probenecid sodium for an additional 239 20 minutes to facilitate the de-esterification of the dye and was carried out in laminin-coated 240 dishes. Cytosolic Ca2+ levels were monitored utilizing a confocal microscope (Leica SP8; Leica, Wetzlar, Germany) operating in line-scan mode at a frequency of 700 Hz. Ca<sup>2+</sup> sparks were 241 242 invoked after a 20-second field stimulation (1Hz, 4ms, 40V) with a stimulator (MyoPacer EP, 243 IONOPTIX). The subsequent detection and quantification of calcium sparks were performed by SparkMaster  $2^{34}$ . 244

## 245 Lipidomic and transcriptomic analysis

246 To extract cardiomyocytes, using ice-cold ethanol to anesthetize neonatal rats (0-3 days) followed 247 by cervical dislocation for euthanasia. Dissect immediately the chest cavity to remove the heart. 248 Place the heart in a petri dish containing cold PBS buffer. Cut the heart into small pieces and 249 isolate cardiomyocytes using a neonatal Cardiomyocyte Isolation Kit, rat (Miltenyi Biotec, 250 Germany) according to its protocol. After 1 hour of differential adherence, the suspending cells 251 were considered cardiomyocytes and were transferred to culture flasks containing DMEM 252 supplemented with 20% FBS for continued culture over 48 hours. Following this, the medium is 253 replaced with serum-free DMEM for 24 hours, after which 1 µM PalGly (dissolved in DMSO) or 254 an equivalent volume of DMSO is added for an additional 24-hour incubation. Subsequently, the

255	culture medium is extracted for lipidomic analysis, and RNA is extracted for RNA-seq
256	transcriptomic analysis. The RNA-seq data can be accessed in the GEO database (GSE278421).
257	We analyzed the altered lipid-related pathways by a lipid pathway enrichment analysis (LIPEA).
258	DEGs and GSEA were analyzed using clusterProfiler 4.10.1.

## 259 Statistical analysis

- 260 Data from the same cells or hearts before and after treatment are analyzed using a paired samples
- 261 t-test, while comparisons between different cell groups are conducted using an two-sided
- 262 independent samples t-test. The concentration-response curves were fitted to a four-parameter Hill
- equation. All analyses were performed in R 4.3.2 and GraphPad Prism 10.2.3.

## 264 Ethics

- 265 The UKB participants gave informed written consent, and ethical approval was obtained from the
- 266 North West Centre for Research Ethics Committee. The deCode participants who donated samples
- 267 gave informed consent, and the National Bioethics Committee of Iceland approved the study. The
- 268 All GWAS human participants provided written informed consent, and all studies had received
- approval from the appropriate ethical review boards.

## 270 **Results**

271 The flowchart of the MR design is presented in Figure 1. Instrument variables used in this study

are presented in Table S2-5.

### Circulating transcripts and proteins that causally associated 273 with the risk of BrS 274

275 The overview of the results of MR and colocalization analysis is presented in Figure 2. A total of

276 nine proteins (H6PD, ANXA4, CXCL6, LRP11, CTSB, DEFB1, PDGFD, SPATA20, GSS) from

- 277 deCode genetics reached the Bonferroni corrected threshold (p < 0.05/1320) among which four
- 278 proteins (CXCL6, CTSB, SPATA20, DEFB1) were with high colocalization support ( $PPH_4 > 0.8$ )
- 279 (Table 1), while 13 proteins (CR1, CXCL6, NAAA, ARSB, HCG22, LTA, CTSB, IGFBP3,
- 280 EPHA1, ECHDC3, AAMDC, ZFYVE19, DCC) from UKB-PPP reached Bonferroni corrected
- 281 threshold (p < 0.05/1590) among which eight proteins (CR1, CXCL6, NAAA, LTA, IGFBP3,
- 282 EPHA1, AAMDC, DCC) were with high colocalization support. In addition, 12 genes at the
- 283 transcript level with high colocalization support from eOTLgen were significantly associated with
- 284 BrS (LUZP1, PCYOX1, NEIL2, MFHAS1, FAM86B3P, SCAND2P, C15orf26, ZSCAN2,
- 285 ADAMTS17, UBTF, DESI1, EP300). Detailed results are presented in Table S6-9. Enrichment
- 286 analysis showed that IGFBP3 and EPHA1 were significantly associated with fibronectin-binding
- (GO:0001968) after FDR adjustments. 287

### 3.2 Circulating protein levels affect genetically proxied ECG 288 morphology 289

290 Despite the main ECG characteristics of BrS present in the right precordial leads, causal inference 291 of circulating proteins on three-lead exercise ECG morphology GWAS may unveil potential 292 mechanisms. For proteins that passed both MR and colocalization thresholds, top cis-pQTLs were 293 selected to represent the expression of the specific proteins (Figure S1). The AAMDC, CXCL6,

294	CTSB, and NAAA affected the slope of the ST segment, higher expression of CXCL6 increased
295	the risk of BrS while causing ST-segment elevation. The SPATA20 was associated with a shift of P
296	wave and PR interval, we postulate that this may be related to the cis-pQTL rs34081637 located at
297	the CACNA1G locus (adjacent downstream of SPATA20). The voltage-dependent calcium
298	channel, T-type, alpha 1G subunit (encoded by CACNA1G) is one of the components of the
299	calcium clock. Unfortunately, we were unable to identify any pQTLs or eQTLs for CACNA1G to
300	proxy its effects on ECG morphology or BrS.

# 301 3.3 IGFBP3 increases the risk of BrS and is mediated by 302 N-palmitoyl glycine

A total of 69 circulating metabolites were nominally significant, and only one metabolite
(N-palmitoyl glycine, PalGly) reached the Bonferroni corrected threshold (p < 0.05/1190) (Table</li>
S9). Genetically proxied circulating PalGly significantly increased the risk of BrS (per SD, OR
1.42, 95% CI 1.20-1.67). Mediation analysis showed that one causally BrS-associated circulating
protein (IGFBP3) increased the risk of BrS partly via PalGly (Table 2).

# 308 3.4 PalGly, IGFBP3, CR1, and DCC reduce the risks of 309 cardiometabolic diseases while CXCL6 increases the risks

To determine potential therapeutic targets for BrS, we performed MR analyses of the genetically proxied PalGly and proteins on 28 cardiometabolic traits. Surprisingly, PalGly reduced the risks of AF and HF, which was in discordance with its effect on BrS (Table 3). The IGFBP3 showed similar effects with the PalGly with reduced cardiometabolic ischemic stroke risk (Table 4). The CXCL6 increased the risk of AF while CR1 and DCC reduced the risk of cardioembolic strokes

and HF respectively. The effects of the CXCL6, CR1, and DCC toward the cardiometabolic traits
were in concordance with their effects towards BrS, indicating these targets were therapeutic.
Detailed results of potential targets on cardiometabolic traits were presented in Table S10.

## 318 **3.5 PalGly may directly bind to BrS-associated proteins**

319 We performed molecular docking of the PalGly with target proteins. The max binding affinities obtained were -5.4 kcal/mol for DCC, -5.8 kcal/mol for CR1, -5.9 kcal/mol for CTSB, -7.6 320 321 kcal/mol for NAAA, -5.8 kcal/mol for EPHA1, -5.7 kcal/mol for IGF1/IGFBP3/ALS complex, 322 and -6.3 kcal/mol for LTA, indicating that the PalGly has the moderate predicted interaction with 323 these targets (Table S11). Docking results also revealed that the PalGly forms three hydrogen 324 bonds and exabits three hydrophobic interactions with DCC, forms three hydrogen bonds and 325 exabits four hydrophobic interactions with CR1, forms two hydrogen bonds and exabits seven hydrophobic interactions with EPHA1, and forms one hydrogen bond and exabits five 326 327 interactions with IGF1/IGFBP3/ALS complex, suggests stable hvdrophobic binding 328 conformations.

# 329 3.6 PalGly does not interact with Nav1.5 but increases 330 calcium sparks of ventricular cardiomyocytes

331 Mutations in the SCN5A gene are the most known in BrS, therefore we first investigated whether 332 PalGly administration under maximum solubility (1  $\mu$ M) can affect peak sodium current (Na<sub>v</sub>1.5), 333 and results showed that the effect was not significant (**Figure 3A**). Next, because the PalGly can 334 induce calcium influx in neurons<sup>35</sup>, we investigate its effect on calcium spark on rabbit primary 335 ventricular cardiomyocytes. After 1  $\mu$ M PalGly infusion and at least 20-second 1 Hz field

stimulations, the amplitude of calcium sparks was significantly increased (Figure 3B) with
increased width, duration, and frequency, while the time to peak of sparks was significantly
reduced.

## 339 **3.7 PalGly activates the hTRPC5 channel**

PalGly activates a TRP-like channel in dorsal root ganglia<sup>35</sup>, and there is speculation that PalGly is 340 a direct transient receptor potential (TRP) channel 5 (TRPC5) agonist<sup>36</sup>. Therefore, we performed 341 342 molecular docking that showed PalGly can bind both class 1 & 2 hTRPC5 channels. The docking 343 results for class 1 hTRPC5 (the dominant one) were presented in Figure 4A, the binding affinity 344 for class 2 hTRPC5 was -5.9 kcal/mol, and PalGly forms two hydrogen bonds in Chain A (Gln507, 345 Trp435) and exhibits five hydrophobic interactions (Chain A: Ile484, Leu491, Leu514; Chain D 346 Thr603, Thr607). Next, expressed hTRPC5 in HEK293 cells perform we to 347 whole-cell patch-clamp recording. The results demonstrated that PalGly significantly increased 348 both inward and outward currents of hTRPC5 at its maximum solubility (1µM), with the outward current increasing by approximately two-fold and the inward current increasing by approximately 349 350 six-fold, and these currents can be diminished by the TRPC5 inhibitor ML204 (Figure 4B). Since 351 1 µM reached the maximum solubility of PalGly, it was not possible to calculate the EC50 value 352 for PalGly activating hTRPC5. Consequently, we calculated the EC50 value for PalGly to be 353 approximately 104 nM (inward current) and 128.3 nM (outward current) by co-administering 20 354 µM of the TRPC5 selective agonist rosiglitazone (Figure 4C).

medRxiv preprint doi: https://doi.org/10.1101/2024.10.21.24315897; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# 355 3.8 PalGly shortens action potential duration and QT 356 interval

357 We subsequently investigated the effects of PalGly on isolated primary rabbit ventricular 358 myocytes and Langendorff-perfused hearts. After administering or perfusing 1 µM PalGly for at 359 least 10 minutes, we observed a significant shortening in the action potential duration (APD) of 360 both cardiomyocytes (Figure 5A) and the overall heart, as well as a significant shortening of the 361 QT interval (Figure 5B). Notably, the influence of PalGly appeared to be more pronounced on 362 early repolarization, as indicated by a greater difference in APD30/MAPD30 compared to APD90/MAPD90. Given that rosiglitazone can suppress several cardiac transmembrane ion 363 currents<sup>37</sup>, we did not use it as a TRPC5 positive control. We further assessed the impact of PalGly 364 365 on OTc through MR analysis, confirming a causal relationship between PalGly and a shortened 366 QTc interval (per SD,  $\beta$  -0.54, 95% CI -1.01, -0.07, p = 0.03).

# 367 3.9 PalGly alters the transcriptomic and lipidomic profile of 368 cardiomyocytes

We added a concentration of 3000 ng/ml of PalGly to the culture medium of primary neonatal rat cardiomyocytes for 24 hours. Mass spectrometry quantification of the culture medium revealed that the PalGly concentration decreased to  $20.18 \pm 16.68$  ng/ml, while in the medium of normally cultured cardiomyocytes, the PalGly concentration was approximately  $0.24 \pm 0.16$  ng/ml. Next, following administration with 1  $\mu$ M PalGly for 24 hours, we extracted the culture medium to perform non-targeted lipidomic analysis, and RNA for RNA-seq and subsequent transcriptomic analysis. Five lipid species were significantly reduced (LPC 18:1, PA 33:1; PA 16:0-17:1, CL 68:3;

376	CL 34:1-34:2, FA 19:1, and PC 32:4e;), while 15 lipid species were significantly increased (FA
377	20:2, FA 22:3, PG 34:0; PG 16:0-18:0, PE 36:1, FA 18:1, FA 18:2, LPE 16:1e, LPE 18:2e, PI 40:5;
378	PI 18:0-22:5, PI 38:5; PI 18:1-20:4, SM d44:3, PS 40:6, PE 40:5; PE 18:0-22:5, PE 40:4, and TAG
379	58:5e; TAG 18:0e-18:1-22:4) (Figure 6A). Enrichment analysis indicated that these lipid
380	alterations were associated with glycerophospholipid metabolism, ferroptosis, and autophagy
381	(Figure 6B). The differential expression genes (DEGs) from RNA-seq are presented in Figure 6C.
382	Gene Ontology (GO) and KEGG enrichment revealed that PalGly not only induces changes in
383	autophagy-related genes but is also associated with alterations in various pathways, including
384	ubiquitin-related pathways, MAPK, and TNF signalling (Figure 6D). Additionally, Gene Set
385	Enrichment Analysis (GSEA) indicated that PalGly negatively regulates the innate immune
386	response (Figure 6E).

## 387 4.0 Discussion

388 Through conducting MR and colocalization analysis involving over 4000 proteins and 1000 389 metabolites, we have identified several previously unreported potential BrS targets as well as 390 discovered the similarities and differences of these targets' effects on BrS and other 391 cardiometabolic disorders. Our MR analysis and colocalization analysis using eQTLs showed minimal overlap compared to the results by pQTLs. Given that proteins are regarded as primary 392 393 function executors, we focused on investigating the proteome/metabolome-wide results. 394 Combining the MR and colocalization results, we found that genetically predicted CXCL6 395 increased the risks of BrS and AF, and CR1 and DCC reduced the risks of BrS, leading to lower 396 risks of cardioembolic stroke and HF respectively. PalGly and IGFBP3, on the other hand,

397 increased the risk of BrS while reducing the risks of cardiometabolic diseases. Interestingly, 398 molecular docking analysis revealed that PalGly not only has the potential to influence BrS risk 399 itself but can also interact with BrS-related proteins (DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, 400 IGF1/IGFBP3/ALS, and LTA). Although mediation analysis indicated that only IGFBP3 exhibited a significant mediating effect. Furthermore, we identified for the first time that PalGly can 401 402 enhance myocardial calcium sparks and shorten action potential duration (APD) and QT interval, 403 with these electrophysiological effects likely mediated by the activation of TRPC5. 404 Although traditionally considered as a pure electrical disorder without structural alteration, 405 there is accumulating evidence suggesting that myocarditis and inflammation infiltration may 406 contribute to BrS pathogenesis <sup>38</sup>, and C-reactive protein (CRP) was found to be an independent 407 marker for symptomatic BrS<sup>39</sup>. Myocardial inflammation was detected in two patients with BrS and arrhythmic storm by fluorodeoxyglucose-positron-emission tomography (FDG-PET)<sup>40</sup>. One 408 409 patient remained free of ICD shocks for 1 year after immunosuppression therapy. However, these studies were either cases or cross-sectional investigations, lacking robust and causal evidence. The 410 411 CXCL6, CR1, and DCC screened by our analyses are proteins associated with immune response. CXCL6 primarily exerts pro-inflammatory effects by recruiting neutrophils<sup>41</sup> and acts as a 412 pro-angiogenic and pro-fibrotic paracrine factor secreted by endothelial cells and cardiac 413 progenitor-like cells<sup>41,42</sup>. Elevated levels of CXCL6 are associated with higher idiopathic 414 415 pulmonary fibrosis mortality<sup>43</sup>. CR1, on the other hand, exerts anti-inflammatory effects by facilitating the clearance of immune complexes and inhibits both C3 and C5 convertase activity<sup>44</sup>. 416 Interestingly, administration of a recombinant form of soluble CR1 (TP10/CDX-1135) led to a 417 418 decreased incidence of cardiovascular events in specifically male individuals undergoing cardiac

surgery on cardiopulmonary bypass<sup>45</sup>. Gender difference is a well-recognized pattern of BrS, 419 female patients with BrS are much rarer<sup>46</sup>, and the cohort included in this study is predominantly 420 421 comprised of male participants (74%), suggesting inflammation may contribute to the gender 422 difference of BrS. DCC is a netrin-1 receptor that is also involved in inflammation and angiogenesis and exerts its cardioprotective effect via Nitric oxide (NO) sustaining<sup>47</sup>. In-vitro 423 424 evidence suggests that the cardioprotective effects exerted by netrin-1 in ischemia-reperfusion 425 injury are by DCC-dependent endothelial-derived and cardiomyocyte-derived NO. Taken together, 426 the immune/inflammation response is likely involved in the pathogenesis of BrS, and 427 pharmacotherapies targeting these targets may hold promise as potential interventions. 428 Lipidomic and transcriptomic analyses indicated that PalGly negatively regulates the innate 429 immune response, a finding that parallels the effects of TRPC5. PalGly is one of the fatty acid

amides that serves as an endogenous signalling molecule<sup>48</sup>. It presents around 250-fold greater 430 amounts in the skin (1612 pmol/g) compared to the amounts in the heart (6 pmol/g)<sup>35</sup>. Under the 431 432 concentration of 27  $\mu$ M, it potently inhibits heat-evoked firing of nociceptive neurons in rat dorsal 433 horn and induced transient calcium influx in adult rat dorsal root ganglion (DRG) cells and a DRG-like cell line (F-11)<sup>35</sup>. Our results demonstrate that PalGly significantly increased the 434 calcium spark amplitude in adult rabbit ventricular cardiomyocytes under field stimulation. 435 436 Additionally, it augmented the width, duration, and frequency of calcium sparks while decreasing 437 the time to peak. PalGly also significantly shortened APD both in vivo and ex vivo and shortened 438 QT interval. We identified PalGly as an endogenous TRPC5 activator through patch-clamp 439 experiments, the agonizing effect can be abolished by the TRPC5 inhibitor ML204. TRPCs contribute to Ca<sup>2+</sup> signalling and changes in cell excitability. TRPC5 channels, like PalGly, are 440

441	predominantly expressed in the brain <sup>49</sup> and exist in a homomeric form or as a heteromer combined
442	with TRPC1/TRPC4/TRPC5 <sup>50</sup> . TRPC5 is a member of the TRP channel family, reportedly
443	involved in cardiovascular pathophysiology <sup>51</sup> . Rosiglitazone, as a TRPC5 agonist, attenuates atrial
444	structural remodelling and atrial fibrillation <sup>52</sup> , which is consistent with our findings that PalGly
445	reduces the risk of AF. However, the underlying mechanism by which PalGly significantly
446	shortens action potential duration (APD), and QT interval and ultimately increases the risk of BrS
447	remains unclear. TRPC5 homomers and heteromers display distinct current-voltage (I-V)
448	relationships. TRPC5 homomer or TRPC5/TRPC4 heteromer shows a doubly rectifying I-V curve
449	characterized by substantial inward currents. In contrast, the TRPC5/TRPC1 heteromer exhibits
450	predominantly outward rectification, manifesting relatively minor inward currents at negative
451	potentials <sup>53</sup> . This distinct rectification behaviour may contribute to the changes observed in action
452	potentials. Additionally, the intracellular calcium increase induced by TRPC5 activation can
453	enhance the activity of calcium-dependent potassium channels (i.e. small conductance
454	calcium-activated potassium channels, SK channels), promoting faster repolarization. PalGly may
455	even directly activate relevant repolarization channels, contributing to these effects.

In addition, It was reported that IGFBP3 is significantly associated with higher sudden cardiac arrest (SCA) and syncope in the SCN5A mutation– BrS patients<sup>54</sup> and higher serum calcium<sup>55</sup>. Our results showed that genetically predicted circulating IGFBP3 is associated with a higher risk of BrS, and the effect is partly mediated by the PalGly.

460 As BrS is relatively rare, we were unable to replicate our current findings through other 461 cohorts. The cohorts available to us consisted of individuals of European ancestry, which may 462 limit the generalizability of our results, particularly considering the higher prevalence of BrS in

- 463 Southeast Asia<sup>56</sup>. We also were unable to perform sex-stratified and mutation-stratified analyses
- 464 due to a lack of available summary-level statistics.
- 465 Collectively, our study underscores the involvement of PalGly, TRPC5, and
- 466 inflammation-related proteins in the pathophysiology of BrS.

## 467 Funding

468 This work was funded by the Chinese National Natural Science Foundation (Grant No. 81930105469 and 82370312).

## 470 Acknowledgements

L.W. is supported by the National Natural Science Foundation of China (No. 82370312 and
81930105). This work was supported by High-performance Computing Platform of Peking
University. The funders had no role in the study design, data collection and analysis, decision to
publish, or preparation of the manuscript. The authors thank members of all contributing studies
for sharing their summary-level GWAS data.

## 476 **Conflict of interests**

477 None declared.

## 478 **Reference**

Brugada, P. & Brugada, J. Right bundle branch block, persistent ST segment
elevation and sudden cardiac death: a distinct clinical and electrocardiographic
syndrome. A multicenter report. *J Am Coll Cardiol* 20, 1391-1396 (1992).

### 482 https://doi.org/10.1016/0735-1097(92)90253-j

- 483 2 Monasky, M. M. et al. Genotype-Phenotype Correlation in a Family with Brugada
- 484 Syndrome Harboring the Novel p.Gln371\* Nonsense Variant in the SCN5A Gene. Int J
- 485 *Mol Sci* **20** (2019). https://doi.org/10.3390/ijms20225522
- 486 3 Milman, A. *et al.* Profile of patients with Brugada syndrome presenting with their first
- 487 documented arrhythmic event: Data from the Survey on Arrhythmic Events in
- 488 BRUgada Syndrome (SABRUS). Heart Rhythm 15, 716-724 (2018).
- 489 https://doi.org/10.1016/j.hrthm.2018.01.014
- 490 4 Barc, J. *et al.* Genome-wide association analyses identify new Brugada syndrome risk
  491 loci and highlight a new mechanism of sodium channel regulation in disease
- 492 susceptibility. *Nat Genet* **54**, 232-239 (2022).
- 493 https://doi.org/10.1038/s41588-021-01007-6
- 494 5 Priori, S. G. *et al.* Executive summary: HRS/EHRA/APHRS expert consensus
  495 statement on the diagnosis and management of patients with inherited primary
  496 arrhythmia syndromes. *Europace* 15, 1389-1406 (2013).
- 497 https://doi.org/10.1093/europace/eut272
- 498 6 Priori, S. G. *et al.* 2015 ESC Guidelines for the management of patients with
  499 ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force
  500 for the Management of Patients with Ventricular Arrhythmias and the Prevention of
  501 Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by:
  502 Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J*
- 503 **36**, 2793-2867 (2015). <u>https://doi.org/10.1093/eurheartj/ehv316</u>

- 504 7 Al-Khatib, S. M. *et al.* 2017 AHA/ACC/HRS Guideline for Management of Patients
- 505 With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive
- 506 Summary: A Report of the American College of Cardiology/American Heart
- 507 Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
- 508 *Circulation* **138**, e210-e271 (2018). https://doi.org/10.1161/cir.00000000000548
- 509 8 Verweij, N. *et al.* The Genetic Makeup of the Electrocardiogram. *Cell Syst* **11**,
- 510 229-238.e225 (2020). https://doi.org/10.1016/j.cels.2020.08.005
- 511 9 Nauffal, V. et al. Monogenic and Polygenic Contributions to QTc Prolongation in the
- 512Population.*Circulation***145**,1524-1533(2022).
- 513 https://doi.org/10.1161/circulationaha.121.057261
- 514 10 Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics
- 515 and disease. *Nat Genet* 53, 1712-1721 (2021).
- 516 https://doi.org/10.1038/s41588-021-00978-w
- 517 11 Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK
- 518 Biobank. *Nature* **622**, 329-338 (2023). <u>https://doi.org/10.1038/s41586-023-06592-6</u>
- 519 12 Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic
- 520 loci and polygenic scores that regulate blood gene expression. *Nature Genetics* 53,
- 521 1300-1310 (2021). https://doi.org/10.1038/s41588-021-00913-z
- 522 13 Chen, Y. *et al.* Genomic atlas of the plasma metabolome prioritizes metabolites 523 implicated in human diseases. *Nature Genetics* **55**, 44-53 (2023). 524 https://doi.org/10.1038/s41588-022-01270-1
- 525 14 Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. Nat

### 526 *Genet* **45**, 1274-1283 (2013). https://doi.org/10.1038/ng.2797

- 527 15 Barton, A. R., Sherman, M. A., Mukamel, R. E. & Loh, P.-R. Whole-exome imputation
- 528 within UK Biobank powers rare coding variant association and fine-mapping analyses.
- 529 Nature Genetics 53, 1260-1269 (2021). https://doi.org/10.1038/s41588-021-00892-1
- 530 16 Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci
- 531 associated with blood pressure traits. *Nat Genet* **50**, 1412-1425 (2018).
- 532 https://doi.org/10.1038/s41588-018-0205-x
- 533 17 Chen, J. et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet
- 534 53, 840-860 (2021). https://doi.org/10.1038/s41588-021-00852-9
- 535 18 Soranzo, N. *et al.* Common variants at 10 genomic loci influence hemoglobin A<sub>1</sub>(C)
- 536 levels via glycemic and nonglycemic pathways. *Diabetes* **59**, 3229-3239 (2010).
- 537 https://doi.org/10.2337/db10-0502
- 538 19 Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body
- 539 mass index in ~700000 individuals of European ancestry. Hum Mol Genet 27,
- 540 3641-3649 (2018). https://doi.org/10.1093/hmg/ddy271
- 541 20 Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects
- 542 identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* **50**, 524-537
- 543 (2018). https://doi.org/10.1038/s41588-018-0058-3
- 544 21 Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association
- 545 meta-analysis of coronary artery disease. *Nat Genet* **47**, 1121-1130 (2015).
- 546 https://doi.org/10.1038/ng.3396
- 547 22 Shah, S. et al. Genome-wide association and Mendelian randomisation analysis

- 548 provide insights into the pathogenesis of heart failure. *Nat Commun* **11**, 163 (2020).
- 549 https://doi.org/10.1038/s41467-019-13690-5
- 550 23 Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated
- 551 population. *Nature* **613**, 508-518 (2023). https://doi.org/10.1038/s41586-022-05473-8
- 552 24 Pattaro, C. et al. Genetic associations at 53 loci highlight cell types and biological
- 553 pathways relevant for kidney function. *Nat Commun* 7, 10023 (2016).
- 554 https://doi.org/10.1038/ncomms10023
- 555 25 Forgetta, V. et al. Rare Genetic Variants of Large Effect Influence Risk of Type 1
- 556 Diabetes. *Diabetes* 69, 784-795 (2020). https://doi.org/10.2337/db19-0831
- 557 26 Xue, A. *et al.* Genome-wide association analyses identify 143 risk variants and
- 558 putative regulatory mechanisms for type 2 diabetes. *Nat Commun* **9**, 2941 (2018).
- 559 https://doi.org/10.1038/s41467-018-04951-w
- 560 27 Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based
- 561 linkage analyses. Am J Hum Genet 81, 559-575 (2007).
- 562 https://doi.org/10.1086/519795
- 563 28 Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
- 564 imprecisely measured traits using GWAS summary data. *PLoS Genet* **13**, e1007081
- 565 (2017). <u>https://doi.org/10.1371/journal.pgen.1007081</u>
- 566 29 Skrivankova, V. W. *et al.* Strengthening the Reporting of Observational Studies in
- 567 Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. Jama
- 568 **326**, 1614-1621 (2021). https://doi.org/10.1001/jama.2021.18236
- 569 30 Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic

- 570 association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
- 571 https://doi.org/10.1371/journal.pgen.1004383
- 572 31 Tofighi, D. & MacKinnon, D. P. RMediation: An R package for mediation analysis
- 573 confidence intervals. *Behavior Research Methods* **43**, 692-700 (2011).
- 574 https://doi.org/10.3758/s13428-011-0076-x
- 575 32 Du, L. *et al.* Dockey: a modern integrated tool for large-scale molecular docking and
- 576 virtual screening. *Brief Bioinform* **24** (2023). <u>https://doi.org/10.1093/bib/bbad047</u>
- 577 33 Zhang, Q. et al. Increase in CO(2) levels by upregulating late sodium current is
- 578 proarrhythmic in the heart. *Heart Rhythm* **16**, 1098-1106 (2019).
- 579 https://doi.org/10.1016/j.hrthm.2019.01.029
- 580 34 Tomek, J., Nieves-Cintron, M., Navedo, M. F., Ko, C. Y. & Bers, D. M. SparkMaster 2:
- 581 A New Software for Automatic Analysis of Calcium Spark Data. *Circ Res* **133**, 450-462
- 582 (2023). https://doi.org/10.1161/circresaha.123.322847
- 58335Rimmerman, N. *et al.* N-palmitoyl glycine, a novel endogenous lipid that acts as a584modulator of calcium influx and nitric oxide production in sensory neurons. *Mol*
- 585 *Pharmacol* **74**, 213-224 (2008). https://doi.org/10.1124/mol.108.045997
- 586 36 Bradshaw, H. B., Raboune, S. & Hollis, J. L. Opportunistic activation of TRP receptors
- 587 by endogenous lipids: exploiting lipidomics to understand TRP receptor cellular
- 588 communication. *Life Sci* 92, 404-409 (2013). https://doi.org/10.1016/j.lfs.2012.11.008
- 589 37 Szentandrássy, N. et al. Effects of rosiglitazone on the configuration of action
- 590 potentials and ion currents in canine ventricular cells. *Br J Pharmacol* **163**, 499-509
- 591 (2011). https://doi.org/10.1111/j.1476-5381.2011.01215.x

- 592 38 Pieroni, M. *et al.* Electroanatomic and Pathologic Right Ventricular Outflow Tract
- 593 Abnormalities in Patients With Brugada Syndrome. *Journal of the American College of*
- 594 *Cardiology* **72**, 2747-2757 (2018).
- 595 https://doi.org/https://doi.org/10.1016/j.jacc.2018.09.037
- 596 39 Bonny, A. *et al.* C-reactive protein levels in the brugada syndrome. *Cardiol Res Pract*
- 597 **2011**, 341521 (2011). https://doi.org/10.4061/2011/341521
- 598 40 Li, A., Tung, R., Shivkumar, K. & Bradfield, J. S. Brugada syndrome-Malignant 599 phenotype associated with acute cardiac inflammation? *HeartRhythm Case Rep* **3**,
- 600 384-388 (2017). https://doi.org/10.1016/j.hrcr.2017.04.011
- 601 41 Gijsbers, K. *et al.* GCP-2/CXCL6 synergizes with other endothelial cell-derived 602 chemokines in neutrophil mobilization and is associated with angiogenesis in
- 603 gastrointestinal tumors. *Exp Cell Res* **303**, 331-342 (2005).
- 604 https://doi.org/10.1016/j.yexcr.2004.09.027
- Torán, J. L. *et al.* CXCL6 is an important paracrine factor in the pro-angiogenic human
  cardiac progenitor-like cell secretome. *Sci Rep* 7, 12490 (2017).
  https://doi.org/10.1038/s41598-017-11976-6
- Bahudhanapati, H. *et al.* Increased expression of CXCL6 in secretory cells drives
  fibroblast collagen synthesis and is associated with increased mortality in idiopathic
  pulmonary fibrosis. *Eur Respir J* 63 (2024).
  https://doi.org/10.1183/13993003.00088-2023
- 612 44 Shandelya, S. M., Kuppusamy, P., Herskowitz, A., Weisfeldt, M. L. & Zweier, J. L.
  613 Soluble complement receptor type 1 inhibits the complement pathway and prevents

- 614 contractile failure in the postischemic heart. Evidence that complement activation is
- 615 required for neutrophil-mediated reperfusion injury. *Circulation* **88**, 2812-2826 (1993).
- 616 https://doi.org/10.1161/01.cir.88.6.2812
- 617 45 Lazar, H. L. et al. Beneficial Effects of Complement Inhibition With Soluble
- 618 Complement Receptor 1 (TP10) During Cardiac Surgery. *Circulation* **116**, I-83-I-88

619 (2007). https://doi.org/doi:10.1161/CIRCULATIONAHA.106.677914

- 620 46 Milman, A. et al. Gender differences in patients with Brugada syndrome and
- 621 arrhythmic events: Data from a survey on arrhythmic events in 678 patients. *Heart*
- 622 *Rhythm* **15**, 1457-1465 (2018). https://doi.org/10.1016/j.hrthm.2018.06.019
- 47 Li, Q., Wang, P., Ye, K. & Cai, H. Central role of SIAH inhibition in DCC-dependent
- 624 cardioprotection provoked by netrin-1/NO. *Proc Natl Acad Sci U S A* **112**, 899-904
- 625 (2015). https://doi.org/10.1073/pnas.1420695112
- 626 48 Ezzili, C., Otrubova, K. & Boger, D. L. Fatty acid amide signaling molecules. *Bioorg*
- 627 *Med Chem Lett* **20**, 5959-5968 (2010). https://doi.org/10.1016/j.bmcl.2010.08.048
- 628 49 Riccio, A. et al. mRNA distribution analysis of human TRPC family in CNS and
- 629 peripheral tissues. Brain Res Mol Brain Res 109, 95-104 (2002).
- 630 https://doi.org/10.1016/s0169-328x(02)00527-2
- 631 50 Bröker-Lai, J. et al. Heteromeric channels formed by TRPC1, TRPC4 and TRPC5
- 632 define hippocampal synaptic transmission and working memory. *Embo j* 36,
- 633 2770-2789 (2017). https://doi.org/10.15252/embj.201696369
- 51 Du, S. L., Jia, Z. Q., Zhong, J. C. & Wang, L. F. TRPC5 in cardiovascular diseases.
- 635 *Rev Cardiovasc Med* 22, 127-135 (2021). https://doi.org/10.31083/j.rcm.2021.01.212

Liu, T., Zhao, H., Li, J., Korantzopoulos, P. & Li, G. Rosiglitazone attenuates atrial

637 structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic 638 rabbits. Cardiovasc Ther 32. 178-183 (2014). 639 https://doi.org/10.1111/1755-5922.12079 640 53 Clapham, D. E. TRP channels as cellular sensors. Nature 426, 517-524 (2003). 641 https://doi.org/10.1038/nature02196 642 54 Juang, J.-M. J. et al. Validation and Disease Risk Assessment of Previously Reported 643 Genome-Wide Genetic Variants Associated With Brugada Syndrome. Circulation: 644 Genomic and Precision Medicine 13, e002797 (2020). 645 https://doi.org/doi:10.1161/CIRCGEN.119.002797 646 55 Van Hemelrijck, M., Shanmugalingam, T., Bosco, C., Wulaningsih, W. & Rohrmann, S. 647 The association between circulating IGF1, IGFBP3, and calcium: results from 648 NHANES III. Endocr Connect 4, 187-195 (2015). https://doi.org/10.1530/ec-15-0039 649 56 Vutthikraivit, W. et al. Worldwide Prevalence of Brugada Syndrome: A Systematic 650 Review and Meta-Analysis. Acta Cardiol Sin 34. 267-277 (2018). 651 https://doi.org/10.6515/acs.201805\_34(3).20180302b

652

636

52

## 653 Author contribution

Conceptualization, H.X.; methodology, H.X., B.L.; software, formal analysis, and investigation,
H.X.; electrophysiology experiments, H.X., B.L., and Y.C.; validation, H.X., B.L.; writing –
original draft, H.X.; writing – review & editing, B.L., L.Y., A.Z., and L.W.; visualization, H.X.,

657 B.L.; funding acquisition, L.W.; supervision, L.W.

## 658 Data availability

eQTLs: www.eqtlgen.org; deCode pQTLs: www.decode.com/summarydata/; UKB-PPP pQTLs:
ukb-ppp.gwas.eu; MetabolitesQTLs: www.ebi.ac.uk/gwas/studies/GCST90199637; Brugada
syndrome: www.ebi.ac.uk/gwas/studies/GCST90086158; ECGwas: http://www.ecgenetics.org;
QTc interval: https://personal.broadinstitute.org/ryank/Nauffal\_2022\_QT\_GWAS\_SAIGE.zip;
RNA-seq generated in this manuscript: GEO database under the code GSE278421.

## 664 Code availability

665 Code for MR can be accessed at github.com/HongxuanXu/Multiomics-brugada-mr.

## 666 Abbreviations

- 667 BrS: Brugada syndrome
- 668 ICD: implantable cardioverter-defibrillator
- 669 MR: mendelian randomization
- 670 ECG: electrocardiogram
- 671 GWAS: genome-wide association studies
- 672 QTL: quantitative trait loci
- 673 PBMC: peripheral blood mononuclear cell
- 674 IVW: Inverse variance weighted
- 675 ApoA1: apolipoprotein A1
- 676 ApoB: apolipoprotein B
- 677 HDL-C: high-density lipoprotein cholesterol
- 678 LDL-C: low-density lipoprotein cholesterol

- 679 Lp(a): Lipoprotein A
- 680 SBP: systolic blood pressure
- 681 DBP: diastolic blood pressure
- 682 HbA1c: Hemoglobin A1C
- 683 BMI: body mass index
- 684 AF: atrial fibrillation
- 685 CHD: coronary heart disease
- 686 HF: heart failure
- 687 PalGly: N-palmitoylglycine
- 688 APD: action potential duration
- 689 FDG-PET: fluorodeoxyglucose–positron-emission tomography
- 690 NO: Nitric oxide
- 691 DRG: dorsal root ganglion
- 692 DAD: delayed afterdepolarizations
- 693 SCA: sudden cardiac arrest

### 695 Table 1. Mendelian randomization analysis and colocalization of circulating proteins and

### 696 transcripts on Brugada syndorme

Data	Exposure	Inverse variance weighted		Colocalization	
source		OR per SD (95% CI)	P value	— Analysis	
				PPH <sub>4</sub>	
deCode	CXCL6	1.26 (1.16-1.36)	3.94E-08	1	
	CTSB	0.78 (0.71-0.86)	1.65E-06	1	
	DEFB1	1.26 (1.13-1.41)	2.78E-05	1	
	SPATA20	0.73 (0.64-0.85)	2.03E-05	1	
UKB-PPP	CXCL6	1.35 (1.22-1.49)	1.39E-08	1	
	CR1	0.80 (0.73-0.87)	1.65E-07	1	
	NAAA	0.87 (0.81-0.93)	1.54E-05	1	
	AAMDC	1.17 (1.09-1.25)	4.32E-06	0.81	
	DCC	0.66 (0.55-0.78)	1.46E-06	0.91	
	EPHA1	0.67 (0.56-0.79)	4.56E-06	1	
	IGFBP3	1.22 (1.12-1.33)	3.59E-06	1	
	LTA	0.88 (0.83-0.92)	1.56E-06	1	
eQTLgen	LUZP1	0.58 (0.48-0.72)	2.66E-07	1	
	PCYOX1	2.37 (1.70-3.30)	3.53E-07	1	
	NEIL2	1.51 (1.39-1.65)	1.74E-20	1	
	MFHAS1	1.66 (1.44-1.91)	3.01E-12	1	
	FAM86B3P	0.40 (0.29-0.55)	1.26E-08	0.95	

C15orf261.73 (1.43-2.10)2.57E-080.93ZSCAN20.35 (0.23-0.53)6.93E-070.83ADAMTS170.60 (0.50-0.74)5.84E-070.96UBTF3.35 (2.05-5.46)1.26E-060.98DES110.53 (0.42-0.67)3.62E-080.85EP3000.62 (0.52-0.74)1.48E-070.95	SCAND2P	0.61 (0.52-0.71)	6.29E-10	1
ZSCAN20.35 (0.23-0.53)6.93E-070.83ADAMTS170.60 (0.50-0.74)5.84E-070.96UBTF3.35 (2.05-5.46)1.26E-060.98DES110.53 (0.42-0.67)3.62E-080.85EP3000.62 (0.52-0.74)1.48E-070.95	C15orf26	1.73 (1.43-2.10)	2.57E-08	0.93
ADAMTS170.60 (0.50-0.74)5.84E-070.96UBTF3.35 (2.05-5.46)1.26E-060.98DESI10.53 (0.42-0.67)3.62E-080.85EP3000.62 (0.52-0.74)1.48E-070.95	ZSCAN2	0.35 (0.23-0.53)	6.93E-07	0.83
UBTF3.35 (2.05-5.46)1.26E-060.98DESI10.53 (0.42-0.67)3.62E-080.85EP3000.62 (0.52-0.74)1.48E-070.95	ADAMTS17	0.60 (0.50-0.74)	5.84E-07	0.96
DESI10.53 (0.42-0.67)3.62E-080.85EP3000.62 (0.52-0.74)1.48E-070.95	UBTF	3.35 (2.05-5.46)	1.26E-06	0.98
EP300 0.62 (0.52-0.74) 1.48E-07 0.95	DESI1	0.53 (0.42-0.67)	3.62E-08	0.85
	EP300	0.62 (0.52-0.74)	1.48E-07	0.95

697

698

### 699 Table 2. The mediation effect of PalGly affects BrS

Protein	Total effect	Direct effect	Direct effect	Mediation		Mediation
		Α	В	effect		proportion
	β (95% CI)	β (95% CI)	β (95% CI)	β (95% CI)	р	_
IGFBP3	0.20 (0.12 to	0.09 (0.05 to	0.35 (0.18 to	0.03 (0.01 to	2.25e-06	3.05 (0.00 to
	0.28)	0.12)	0.51)	0.04)		24.91)

'Total effect' indicates the effect of the circulating proteins on BrS, 'Direct effect A' indicates the
effect of the circulating proteins on PalGly, 'Direct effect B' indicates the effect of PalGly on BrS,
'Mediation effect' indicates the effect of the circulating proteins on BrS through PalGly. Total
effect, direct effect A and direct effect B were derived by IVW; mediation effect was derived by
Delta method.

### 706 Table 3. Mendelian randomization analysis of PalGly, IGFBP3 CXCL6, CR1, and DCC on

### 707 cardiometabolic diseases

Exposure	Cardiom	Inverse variance weighted		Weighted median	
	etabolic trait	OR per SD (95%	р	OR per SD	р
		CI)		(95% CI)	
PalGly	AF	0.97 (0.94-0.99)	0.005	0.96 (0.93-1.00)	0.03
	HF	0.96 (0.93-0.99)	0.01	0.96 (0.92-1.00)	0.04
IGFBP3	AF	0.94 (0.92-0.96)	4.21E-11	0.96 (0.93-0.98)	6.61E-0
					4
	Stroke	0.96 (0.94-0.99)	0.002	0.95 (0.91-0.98)	0.006
	Ischemi	0.91 (0.87-0.96)	3.91E-04	0.93 (0.86-0.99)	0.03
	c stroke				
	(cardioe				
	mbolic)				
	Ischemi	0.91 (0.85-0.97)	0.004	0.89 (0.81-0.97)	0.01
	c stroke				
	(large				
	artery				
	atherosc				
	lerosis)				
CXCL6	AF	1.03 (1.01-1.05)	0.003	1.04 (1.01-1.06)	0.01

CR1	Ischemi	0.92 (0.88-0.97)	0.002	0.93 (0.86-1.00)	0.04
	c stroke				
	(cardioe				
	mbolic)				
DCC	HF	0.91 (0.87-0.95)	2.37E-05	0.92 (0.86-0.98)	0.007

708

709 Table 4. Mendelian randomization analysis of PalGly, IGFBP3, CXCL6, and CR1 on

Exposure	Cardiom	Inverse variance weighted				Weighted median			
	etabolic fator	β per CI)	SD (9	5%	р	β per CI)	SD (9	5%	р
PalGly	HDL-C	-0.06	(-0.11	to	0.04	-0.05	(-0.10	to	0.03
		0.00)				0.00)			
IGFBP3	SBP	-0.60	(-0.70	to	2.07E-27	-0.65	(-0.79	to	8.47E-1
		-0.49)				-0.50)	8		
	DBP	0.24	(0.17	to	4.36E-12	0.24	(0.16	to	2.73E-0
		0.31)				0.32)			9
	Two-ho	0.11	(0.03	to	0.01	0.08	(0.01	to	0.03
	ur	0.20)				0.15)			
	glucose								
	challeng								

710 cardiometabolic factors

	e									
	Waist	-0.03	(-0.05	to	2.67E-04	-0.03	(-0.05	to	0.004	
	circumf	-0.02)			-0.01)					
	erence									
	Waist-to	-0.02	(-0.03	to	0.01	-0.02	(-0.04	to	0.03	
	-hip	-0.01)				-0.00)				
	ratio									
CXCL6	HbA1C	-0.03	(-0.04	to	3.34E-05	-0.02	(-0.03	to	0.002	
		-0.01)			-0.01)					
	Waist-to	0.02	(0.00	to	0.03	0.02	(0.00	to	0.03	
	-hip	0.04)				0.04)				
	ratio									
CR1	Total	0.08	(0.02	to	0.08	0.07	(0.00	to	0.04	
	choleste	0.13)				0.14)				
	rol									





715 Figure 1. Flowchart of the MR design





717 Figure 2. Manhattan plot of significant proteins and transcripts. Red symbols indicate high 718 colocalization support. (A) Proteins from deCode. (B) Proteins from UKB-PPP. (C) Transcripts 719 from eQTLgen.





721 Figure 3. Sodium current and calcium spark traits induced by the palmitoylglycine.

722 (A) Left: representative peak sodium current (Na<sub>v</sub>1.5) before and after the PalGly administration 723 in resting state or half inactivation state. The maximum solubility of palmitoylglycine in 724 extracellular fluid is around 1  $\mu$ M. Right: normalized current before and after PalGly (n = 5, 725 paired t-test). (B) Left top: representative image of calcium in primary ventricular cardiomyocytes 726 dyed by Fluo4, AM. Left bottom: representative image (standard deviation transformed) of 727 calcium sparks after 20-second 1 Hz filed stimulations. Right: Delta F/F0 representing the 728 amplitude of calcium sparks is significantly higher after PalGly administration (nControl = 11, 729 nPalGLy = 38 from 5 rabbits, unpaired t-test), each dot represents a mean value of calcium sparks 730 of one line-scanned ventricular cardiomyocyte. PalGly: palmitoylglycine.



731

732 Figure 4. PalGly binds to and agonizes the hTRPC5 channel

733 (A) molecular docking result for PalGly and class 1 hTRPC5. Chain C of hTRPC5 is in cyan, 734 PalGly is in orange, and hydrogen bonds are in magentas. The binding affinity is -5.9 kcal/mol, 3 735 hydrogen bonds (Gln503, Trp435, Asp433) are formed between PalGly and Chain C of hTRPC5, 736 and 10 hydrophobic interactions (Chain C: Trp435, Met438, Ala441, Ile484, Ile487, Leu491, 737 Leu514, Leu488; Chain D: Thr603, Thr607) are formed. The normalized agonizing effect of PalGly is presented in (B), ML204 is a selective TRPC4/TRPC5 channel inhibitor ( $\geq$  3 cells from 738 739 3 dishes, paired t-test). (C) Normalized stimulation curve of PalGly combing rosiglitazone, a 740 TRPC5 activator ( $\geq$  5 cells from 3 dishes). The top two panels are representative recordings of



### 741 hTRPC5 current, outward current is in blue, and inward current is in green.

743 Figure 5. PalGly shortens action potential duration and QT interval

744 (A) APD traits of isolated primary rabbit ventricular cardiomyocytes before and after PalGly 745 administration (n = 8 from 3 rabbits, paired t-test), representative recording is on the left. (B) ECG 746 and APD traits of isolated Langendorff-perfused rabbit hearts (n = 8, paired t-test), representative 747 ECG recording is on the top left and APD recording on the bottom right. APA: action potential 748 amplitude. APD: action potential duration.



749

750 Figure 6. PalGly alters the transcriptomic and lipidomic profile of neonatal rat cardiomyocytes

751 (A) Volcano plot and heatmap of differential lipids. (B) LIPEA lipids enrichment. (C) Significant

752 differential expressed genes. (D) GO and KEGG enrichment. (E) GSEA analysis, GO categories

753 are on the left and middle, and KEGG categories are on the right.



755 Figure. S1 Circulating protein levels affect genetically proxied ECG morphology. Top

756 cis-pQTLs were selected to represent the expression of the specific proteins

757

medRxiv preprint doi: https://doi.org/10.1101/2024.10.21.24315897; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .









Η





J

delta F/F0









PalGly Vehicle





G

p = 0.0070 0.5 ¬ 0.4 -0.3-0.2 -0.1 -0.0 -Vehicle PalGly































- FC\_Up\_Only (208)
- pVal\_Only (5)





Α



LIPEA Pathway Enrichment



spindle

ubiquitin ligase complex

nuclear envelope

Golgi membrane

actin cytoskeletor







Rap1 signaling pathway

Proteoglycans in cancer

Autophagy – animal





MF of GO enrichment barplot

protein-macromolecule adaptor activity GTPase binding ubiquitin-like protein transferase activity aminoacyltransferase activity ubiquitin-protein transferase activity ubiquitin-like protein ligase binding ubiquitin protein ligase binding small GTPase binding GTPase regulator activity

transcription coregulator

activity

nucleoside-triphosphatase regulator activity catalytic activity, acting on RNA RNA polymerase II-specific DNA-binding transcri... ubiquitin-like protein ligase activity catalytic activity, acting on DNA

process utilizing autophagic

autophagy ·



mitotic cell cycle phase transition regulation c protein-containing complex assembly







100

200

Gene Number

300

400

Β







-0.5 0.0

